Amgen's drug, MariTide, is taken less frequently than Novo Nordisk's Wegovy and Eli Lilly's Zepbound, and may cause ...

Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a ...

The other drugs often referred to as “Ozempic” are Wegovy, Mounjaro, and Zepbound, the third of which was approved by the FDA ...

The active ingredients in these popular type 2 diabetes treatments are being used to treat a wide range of health conditions.

The FDA anticipates limited availability of most doses of the GLP-1 weight loss drugs Wegovy and Zepbound at least through ...

The U.S. Food and Drug Administration (FDA) approved Zepbound for the treatment of obesity in November 2023. Some prescribe ...

Eli Lilly shares popped early Tuesday after the drugmaker reported first-quarter profit that topped estimates amid strong ...

Eli Lilly missed on total sales in the first quarter, but its GLP-1 drugs helped boost sales by 26% over those in Q1 2023.

Eli Lilly raised its full-year guidance while it reported strong first-quarter sales of Zepbound, its obesity drug.

A new clinical trial from drugmaker Eli Lilly shows that Zepbound and Mounjaro reduced obstructive sleep apnea symptoms.

"Demand continues to outstrip even increased supply," Eli Lilly's CFO said of its Zepbound weight loss drug on the company's ...

Lilly Rides Mounjaro, Zepbound to Better-Than-Expected 1Q Profit Despite Supply Issues Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro ...